Lucia Musacchio

Rome, 00168, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Journal: Cancers

Published: May 06, 2026

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 17, 2026

Advances in treatment strategies for low-grade serous ovarian cancer.

Advances in treatment strategies for low-grade serous ovarian cancer.

Journal: Cancer treatment reviews

Published: June 26, 2025

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

Journal: ESMO open

Published: April 30, 2025

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Journal: ESMO open

Published: April 29, 2025

Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus.

Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 27, 2024

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

Journal: ESMO open

Published: November 10, 2024

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.

Journal: Expert review of anticancer therapy

Published: June 12, 2024

Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.

Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.

Journal: Therapeutic advances in medical oncology

Published: March 27, 2024

Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA.

Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 11, 2024

Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.

Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.

Journal: Critical reviews in oncology/hematology

Published: January 30, 2024

Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.

Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.

Journal: Cancer treatment reviews

Published: December 22, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026